Author
Listed:
- Natalia Espinola
(Institute for Clinical Effectiveness and Health Policy (IECS))
- Constanza Silvestrini
(Institute for Clinical Effectiveness and Health Policy (IECS))
- Carla Colaci
(Institute for Clinical Effectiveness and Health Policy (IECS))
- Daniela Sugg
(Sugg y Asociados Consultancy
University of Chile
University of Diego Portales
Universidad Andrés Bello)
- Carlos Rojas-Roque
(Institute for Clinical Effectiveness and Health Policy (IECS)
University of York)
- Jesica Coelli
(Institute for Clinical Effectiveness and Health Policy (IECS))
- Federico Augustovski
(Institute for Clinical Effectiveness and Health Policy (IECS))
Abstract
Objectives The aim of this study was to perform a budget impact analysis (BIA) of introducing olaparib treatment for adult patients with metastatic castration-resistant prostate cancer in Argentina. Methods A BIA model was used to estimate the cost difference between the current scenario (without olaparib) and the new scenario (incorporation of olaparib) for a third-party payer over a 5-year time horizon. The budgetary impact is estimated at the national health system level and by healthcare sectors in Argentina. Input parameters were obtained from the literature and validated by local expert opinion. Direct medical costs were obtained from both the Institute for Clinical Effectiveness and Health Policy (IECS) unit cost database and public data in Argentina. The microcosting estimation was used for key variables of the analysis. All costs are reported in US dollars (US$) as for October 2022 (1 US$ = 152.59 Argentine pesos). One-way sensitivity analyses and scenario analyses were conducted to evaluate the model robustness. Results The incorporation of olaparib, with a wholesale price per pack of US$3176, was associated with a weighted average of the budget impact per member per month (PMPM) of US$0.0191 for the national health system, being slightly higher than the estimated budgeted high impact threshold (US$0.0153). The PMPM budget impact for a 5-year average ranged between US$0.007 (public sector) and US$0.033 (private sector). The duration of treatment with olaparib was the most influential parameter in the budget impact results. Conclusions The introduction of olaparib for the treatment of metastatic castration-resistant prostate cancer has a high budget impact for Argentina's health system. These findings are informative to support policy decisions aimed to expand the current treatment landscape for prostate cancer.
Suggested Citation
Natalia Espinola & Constanza Silvestrini & Carla Colaci & Daniela Sugg & Carlos Rojas-Roque & Jesica Coelli & Federico Augustovski, 2024.
"Budget Impact Analysis of Olaparib for the Management of Patients with Homologous Recombination Repair (HRR)-Mutated Castration-Resistant Metastatic Prostate Cancer in Argentina,"
PharmacoEconomics - Open, Springer, vol. 8(5), pages 727-738, September.
Handle:
RePEc:spr:pharmo:v:8:y:2024:i:5:d:10.1007_s41669-024-00508-4
DOI: 10.1007/s41669-024-00508-4
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharmo:v:8:y:2024:i:5:d:10.1007_s41669-024-00508-4. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.